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Angiosarcomas are rare malignant tumors with a heterogeneous clinical presentation and generally poor
prognosis. It has been difficult to establish consistent molecular characteristics and driver events in angio-
sarcoma development. Oncogenic and angiogenesis-related pathways have been investigated pre-clinically and
clinically with varying results. A few promising responses to checkpoint inhibitors have been described, but
immunological features require further elucidation. With this review we present an overview of the critical
biological pathways and processes affected in angiosarcoma, and their potential role in novel, non-cytotoxic,
systemic treatments.
1. Introduction
Angiosarcoma is a rare type of sarcoma, comprising about 1–2% of
all sarcomas. Until this day, its underlying mechanisms remain mostly
unclear, although angiosarcomas are thought to arise along the differ-
entiation from mesenchymal stem cell to endothelial (progenitor) cell.
The clinical classification of angiosarcomas is mostly based on etiology
and/or tissue of origin. Primary angiosarcomas can be distinguished
from secondary angiosarcomas which arise due to previous radiation
therapy, chronic lymphedema or exposure to vinyl chloride. Median
age at diagnosis is between 52 and 67 years (range 0.2–91) (Fayette
et al., 2007; Buehler et al., 2014). The reported male to female ratio
varies strongly, between 1:0.8 and 1:1.5 (Buehler et al., 2014; Abraham
et al., 2007), which is partly due to the different subtypes described
within the cohorts. Clinically, there appears to be a difference in clinical
behavior based on location of the primary tumor. For instance, cuta-
neous angiosarcoma of the head and neck region occurs mainly in el-
derly men as a consequence of UV light exposition of the scalp (Patel
et al., 2015), whereas angiosarcoma of the breast tends to present at a
much younger age (median 35–54 years), almost exclusively in female
patients and most often after radiotherapy of breast cancer (Yin et al.,
2017).
In case of limited, local disease, treatment consists of resection,
often combined with radiotherapy. Patients with locally advanced or
metastatic disease are treated with systemic therapy, either paclitaxel
or doxorubicin. In case of cutaneous angiosarcoma, a favorable re-
sponse was seen with weekly paclitaxel compared to doxorubicin
(Italiano et al., 2012a). Despite this treatment, overall survival after
primary diagnosis remains poor, with a reported 5-year survival of
30–40% (Fayette et al., 2007; Fury et al., 2005), compared to 50–60%
for soft tissue sarcomas in general (Mocellin et al., 2006). Once me-
tastasized, the reported median overall survival is only 3–12 months
(Fayette et al., 2007; Buehler et al., 2014; Abraham et al., 2007; Lahat
et al., 2010). So far, patients with angiosarcoma have had limited
benefit from the recent breakthroughs in oncology, such as targeted
therapy and immunotherapy.
With this review, we aim to present an overview of the critical
biological pathways and processes affected in angiosarcoma, and their
potential role in novel, non-cytotoxic, systemic treatments.
2. Targets for treatment
2.1. Angiogenesis-related targets
Several components involved in the regulation of angiogenesis have
been investigated in angiosarcoma, both on a genetic level as well as on
a protein level.
2.1.1. VEGF-pathway
One of the most investigated pathways in angiosarcomas is the
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VEGF-pathway. VEGFR2/KDR (Vascular Endothelial Growth Factor
Receptor 2 or Kinase Insert Domain Receptor) is the main VEGF re-
ceptor on normal endothelial cells. In about 10% of angiosarcomas
mutations have been found in the VEGFR2 gene (Table 1) (Huang et al.,
2016). FLT4 (Fms Related Tyrosine Kinase 4, or VEGFR3), becomes
upregulated during physiological angiogenesis. Amplification of FLT4
has been demonstrated in 11–25% of secondary angiosarcomas and
often co-occurs with MYC amplification (Huang et al., 2016; Guo et al.,
2011). Interestingly, only one out of 73 primary angiosarcomas har-
bored an FLT4 amplification (1.4%) (Huang et al., 2016).
VEGFR1 and VEGFR2 interact with VEGF-A (a known promoter of
angiogenesis) in both normal as well as in malignant endothelial cells.
Immunohistochemical expression of VEGF-A, VEGRF1 and VEGFR2 was
shown to be present in 65–95% of angiosarcoma cases (Itakura et al.,
2008; Zietz et al., 1998). Low or absent VEGFR2 expression was asso-
ciated with poor survival. However, given the discrepancy between the
low prevalence of VEGFR mutations and positive immunochemical
expression, it would be useful to directly compare mutational status and
protein expression in order to gain insight in their actual correlation.
2.1.1.1. Bevacizumab. Bevacizumab is an anti-VEGF monoclonal
antibody and has been tested in angiosarcoma both pre-clinically as
well as in clinical studies. When applied as monotherapy in pre-clinical
experiments, bevacizumab showed variable efficacy varying from no
effect in vitro and in vivo (Young et al., 2014; Hoshina et al., 2013), to a
strong reduction in cell growth in vitro (Tables 2 and 3) (Azzariti et al.,
2014). In vitro combination of bevacizumab with paclitaxel in
angiosarcoma showed an additive rather than synergistic effect
(Table 4) (Young et al., 2014). In the first clinical study in
angiosarcoma patients, single agent bevacizumab showed partial
response (PR) in 9% (2/23) and stable disease (SD) in 48% (11/23)
of patients at 6 weeks (Table 5) (Agulnik et al., 2013). Median
progression free survival (PFS) and overall survival (OS) were 12.0
and 52.7 weeks, respectively. In a randomized angiosarcoma specific
phase II trial with 50 patients, the combination of bevacizumab and
paclitaxel did not show improvement compared to paclitaxel alone
(Ray-Coquard et al., 2015). A second, non-randomized trial showed no
significant difference of weekly paclitaxel versus paclitaxel every three
weeks, both combined with bevacizumab (Bui et al., 2018). Median PFS
was 5.4 months for weekly paclitaxel/bevacizumab and 3.4 months in
the three weekly group, respectively. Combination of bevacizumab with
gemcitabine and docetaxel was investigated in soft tissue sarcoma (STS)
patients, where three out of five angiosarcoma patients included (60%)
had a partial response (Dickson et al., 2015).
2.1.1.2. TKI’s targeting VEGFR. Pazopanib is a multi-targeting TKI
(tyrosine kinase inhibitor) approved for second and higher line
treatment of STS patients, targeting PDGFR, VEGFR1, 2 and 3. A
retrospective analysis of 40 angiosarcoma patients treated in the
PALETTE study with pazopanib showed a response rate of 20% (PR
8/40 patients) (Kollar et al., 2017; van der Graaf et al., 2012). Median
PFS was 3 months (95% CI 2.1–4.4) compared to 4.6 months in the total
STS population (Young et al., 2014). In a phase IB/IIA clinical trial
testing pazopanib in combination with anti-endoglin antibody TRC105
in soft tissue sarcoma patients, encouraging activity was seen in
angiosarcoma patients with durable complete response (CR) in 2/5
angiosarcoma patients enrolled (Attia et al., 2016). A randomized phase
III trial comparing single agent pazopanib with pazopanib and TRC105
in angiosarcoma patients is currently ongoing (NCT02979899).
Endoglin (or CD105) is a transforming growth factor β (TGFβ) co-
receptor which is required for angiogenesis and is considered to be
important in preventing resistance against VEGF-inhibition. In
angiosarcoma, endoglin expression was present on tumor cells in the
vast majority of cases (Verbeke et al., 2013). No pre-clinical
experiments targeting endoglin in angiosarcoma have been reported
yet.Ta
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Sorafenib, a RAF kinase inhibitor also targeting VEGFR2 and 3, has
been examined in a phase 2 study with STS patients (Maki et al., 2009).
Out of 37 angiosarcoma patients included in the study, 5 had a partial
response (RR 14%), and median PFS in the angiosarcoma cohort was
3.8 months. Based on these findings, an angiosarcoma-specific phase II
trial was performed with 41 patients (Ray-Coquard et al., 2012). In this
study the median PFS was only 1.8 months for superficial angio-
sarcoma, and 3.8 months for visceral angiosarcoma.
In vitro treatment of a secondary breast angiosarcoma patient-de-
rived cell line with vandetanib, a TKI targeting VEGFR2, led to a strong
reduction of proliferation (Azzariti et al., 2014). These results have not
yet been confirmed in vivo or clinically. Axitinib (inhibiting VEGFR1, 2
and 3 activity) failed to induce cell death as monotherapy in vitro, but
yielded an additive effect in combination with paclitaxel (Young et al.,
2014). A multi strata phase 2 study with axitinib, including an arm with
angiosarcoma patients, has been performed and results are awaited
(NCT01140737). Sunitinib (a TKI targeting among others VEGFR1, 2
and 3) was tested both in vitro and in vivo, but didn’t show a cytotoxic
effect (Young et al., 2014; Hoshina et al., 2013). Only a few angio-
sarcoma patients treated with sunitinib have been reported (Yoo et al.,
2009; Silva et al., 2015). A phase II clinical study is currently in-
vestigating the effects of regorafenib (targeting the VEGF-receptors
among others), in angiosarcoma patients specifically (NCT02048722).
2.1.2. Angiopoietin-Tie pathway
The Angiopoietin-Tie pathway is another important signaling
pathway regulating angiogenesis through its role in remodeling and
maturation of blood vessels. Part of this pathway is the endothelium-
specific tyrosine kinase receptor Tie2 kinase, interacting with
Angiopoietin 1 and 2 (Ang1 and 2) ligands. This complex interaction
can result in both pro-angiogenic as well as anti-angiogenic effects.
Immunohistochemistry expression of Angiopoietin-Tie-pathway pro-
teins was shown in a study of 51 angiosarcoma patients, with Ang1,
Tie1 and Tie2 being expressed in the majority of cases (68–86%) and
Ang2 in 42% (Buehler et al., 2013). By univariate analysis, Ang1 ex-
pression was correlated with improved survival. However, data re-
garding the correlation between genetic aberrations and im-
munohistochemical expression are lacking.
Pharmacological inhibition of Tie2 kinase with CAS 948557-43-5
was investigated in murine angiosarcoma cell lines, resulting in a dose
dependant reduction of cell survival (Hasenstein et al., 2012). Combi-
nation with VEGF inhibitor sunitinib yielded a synergistic effect in vitro
and showed a stronger reduction of tumor volume in vivo compared to
both monotherapies. This synergism may be explained by Ang2 func-
tion switching from anti-angiogenic to pro-angiogenic in the presence
of VEGF (Amo et al., 2004). Clinical trials with CAS 948557-43-5 have
not yet been reported.
Trebananib, which targets the Angiopoietin-Tie interaction by se-
questering Angiopoietin 1 and 2, was tested in 16 angiosarcoma pa-
tients in a phase II study (D’ Angelo et al., 2015). The drug was well
tolerated but unfortunately did not lead to confirmed responses, with
median PFS of only 1.6 months (95% CI 1.41–1.74). Given the above
mentioned in vivo synergy of CAS 948557-43-5 with sunitinib, combi-
nation of trebananib with other TKIs might be more promising than
monotherapy.
Both angiopoietin and VEGFR2 signaling can be inhibited by PTPRB
(Protein Tyrosine Phosphatase Receptor B), a negative regulator of
angiogenesis. PTPRB mutations were found in 26% (10/39) of angio-
sarcomas (Behjati et al., 2014). All of these PTPRB mutated tumors
were either known to be secondary angiosarcoma and/or had MYC
amplification, a biomarker frequently, though not exclusively, asso-
ciated with radiation-associated angiosarcoma. In addition, in 7 and
20% of angiosarcoma cases respectively, a mutation in PLCG1 (Phos-
pholipase C Gamma 1, a known signal transducer for tyrosine kinases)
was found (Huang et al., 2016; Behjati et al., 2014). Transfection of this
mutation into normal endothelial cells led to apoptosis resistance and
invasiveness in vitro (Kunze et al., 2014). Neither PTPRB nor PLCG1 can
yet be directly inhibited.
2.1.3. Other targets – angiogenesis
Secreted frizzled related protein 2 (SFRP2) is a stimulator of an-
giogenesis. Positive immuno-histochemical staining of SFRP2 was
found in 9/9 (100%) angiosarcoma samples (Courtwright et al., 2009).
Further investigation of its function in angiosarcoma revealed that
SFRP2 mediates angiogenesis through a calcineurin-dependent NFAT
(Nuclear Factor of Activated T-cells) pathway. The drug tacrolimus
interferes with this pathway through inhibition of calcineurin, thereby
indirectly inhibiting SFRP2 effects. In vivo treatment of the murine SVR
angiosarcoma tumor model with tacrolimus significantly reduced
tumor growth with 46% (Courtwright et al., 2009). Treatment of
murine angiosarcoma cells with a SFRP2 monoclonal antibody (mAb)
inhibited endothelial cell tube formation and migration in vitro, without
effect on proliferation (Fontenot et al., 2013). In vivo, treatment of
angiosarcoma with SFRP2 mAb did result in about 55–60% growth
inhibition. There are no clinical trials yet with SFRP2 targeting agents
or tacrolimus, although this does appear to be an effective approach.
ROCK1 and 2 (Rho-Associated Kinases) are modulators of angio-
genesis through regulation of cell shape and cytoskeleton in endothelial
cells. Disruption of ROCK signaling has been reported to inhibit VEGF-
mediated activation of endothelial cells (Bryan et al., 2010). Over-
expression of ROCK1 was present in all angiosarcoma samples (n=6),
whereas ROCK2 was overexpressed in both benign and malignant
vascular tumors (Amaya et al., 2017). ROCK1 and 2 knockdown in
angiosarcoma cells led to reduced tumor weight in vivo (Amaya et al.,
2017; Montalvo et al., 2013). ROCK2 knockdown displayed a stronger
inhibitory effect on tumor growth than knockdown of ROCK1 in both
studies. Rho-kinase inhibitors have been clinically tested, though not
yet in solid tumors.
Angiogenesis can also be targeted through blockade of beta-adre-
nergic receptors by propranolol, which exerts its effect through vaso-
constriction, decreased responsiveness to VEGF, and induction of
apoptosis. In angiosarcoma, strong expression of three beta-adrenergic
receptors was present in 21–48% of cases (Stiles et al., 2013). In vitro
treatment of canine and mouse angiosarcoma cells with propranolol
Table 3
In vivo experiments with targeted therapy.
Compound Target(s) Xenograft Result Ref
Bevacizumab VEGF HAMON No effect on tumor growth or survival duration. (Hoshina et al., 2013)
Sunitinib VEGFR1/ VEGFR2/ VEGFR3, PDGFR, KIT, FLT3,
CSF-1R, RET
HAMON No effect on tumor growth or survival duration. (Hoshina et al., 2013)
SVR (murine AS) Reduction of tumor volume (44%, day 20) (Hasenstein et al., 2012)
CAS 948,557-43-5 Tie2 kinase SVR (murine AS) Reduction of tumor volume (61%, day 20) (Hasenstein et al., 2012)
Tacrolimus Calcineurin SVR (murine AS) Reduction of tumor volume (46%, day 19) (Courtwright et al., 2009)
SFRP2 monoclonal Ab Secreted Frizzled Related Protein 2 SVR (murine AS) Reduction of tumor volume (55-60%) (Fontenot et al., 2013)
Propranolol Beta adrenergic receptor SVR (murine AS) Reduction of tumor size and weight. (Stiles et al., 2013)
TRAM-34 KCa3.1 ISO-HAS Suppression of development of tumors, decreased
tumor weight.
(Chen et al., 2016)
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resulted in blockade of cell proliferation and induction of apoptosis. Its
cytotoxic effects were selective for vascular tumor cells, and a sy-
nergistic effect was found when combined with cisplatin, busulfan and
vincristine. In vivo treatment with single agent propranolol resulted in
reduced angiosarcoma tumor growth. Analysis of propranolol treatment
effects revealed upregulation of TEK expression, a gene encoding for
Tie2 receptor (Stiles et al., 2013). Clinically, responses to combination
treatment of propranolol with cyclophosphamide or paclitaxel have
been described in three case reports (Banavali et al., 2015; Daguze
et al., 2016; Chow et al., 2015). Immunostaining for beta adrenergic
receptors was reported positive in two of the cases. Based on in vitro
assessment of propranolol combinations which showed synergy with
vinblastine, seven patients received treatment of propranolol with
weekly vinblastine and methotrexate (Pasquier et al., 2016). Treatment
was well tolerated and resulted in clinical responses in all patients,
varying from partial response to complete clinical and metabolic re-
sponse. It is unclear whether this effect is related to the propranolol, the
metronomic schedule of the chemotherapy, or the combination.
The vascular disruptive agent vadimezan, which reduces tumor
blood flow and induces tumor necrosis, significantly inhibited angio-
sarcoma cell growth in vitro (Hoshina et al., 2013). Its clinical effect
seemed promising in non-angiosarcoma phase I and –II trials, but has
not yet been confirmed in phase III trials and no angiosarcoma trials are
initiated so far (Daei Farshchi Adli et al., 2017).
In conclusion, angiogenesis-related genes and proteins have been
rather extensively studied as a therapeutic target in angiosarcoma.
However, clinical success of angiogenesis-targeting agents is lacking so
far. Whether angiogenesis-related markers in angiosarcoma indicate a
substantial role in angiosarcoma pathogenesis or merely reflect the
degree of tumor cell differentiation, requires further investigation.
2.2. Oncogenic pathways in angiosarcoma
2.2.1. RAS/RAF/MEK/Erk -pathway
The RAS/RAF/MEK/Erk pathway is known to play a critical role in
survival of human cancer cells. Mutated genes can lead to induced or
sustained activation of the pathway, such as mutations in signal
transducers (RAS) or downstream kinases within the pathway (BRAF).
Genetic alterations involving the RAS/RAF/MEK/Erk pathway have
been reported in 13–53% of angiosarcoma cases (Murali et al., 2015;
Behjati et al., 2014). However, specific assessment of the mutational
status of NRAS and BRAF performed in another series of 52 angio-
sarcoma cases showed no mutations (Italiano et al., 2012b).
An attempt to inhibit the RAS/RAF/MEK/Erk-pathway with the
MEK-inhibitor selumetinib yielded varying responses in vitro, inhibiting
cell growth in the AS-M5 cell line but with only minimal effect in ISO-
HAS cells (Young et al., 2014). Both a RAF-inhibitor (PLX4720) and a
MEK inhibitor (PD0325901) were tested in different angiosarcoma cell
lines (Wada et al., 2015). The RAF inhibitor did not induce cell death,
and the MEK inhibitor only induced weak responses. Combination
therapy of the MEK inhibitor with the mTOR (mammalian target of
rapamycin) inhibitor rapamycin appeared to render canine angio-
sarcoma cells as sensitive for MEK inhibition as BRAF-positive mela-
nomas (Andersen et al., 2015). In vivo, combined MEK and mTOR in-
hibition significantly reduced tumor growth. Treatment with mTOR or
MEK inhibitor alone was less effective than the combination, possibly
because resistance to MEK inhibition might develop via activation of
the MAPK pathway upon mTOR inhibition (Carracedo et al., 2008).
2.2.2. PI3K/AKT/mTOR-pathway
Another oncogenic pathway of interest in angiosarcoma is the PI3K/
AKT/mTOR-pathway, which is known to control cell survival, cell
growth and cell cycle progression in both physiological conditions as
well as in malignant cells. It can be activated through RAS mutation,
loss of PTEN (phosphatase and tensin homolog) or increased expression
of growth factor receptors such as Epidermal Growth Factor Receptor
(Karar and Maity, 2011).
Both genetic alterations as well as (over)expression of downstream
components of the PI3K/AKT/mTOR pathway indicate its involvement
in angiosarcoma. Mutations of the PIK3CA gene (encoding PIK3) has
been reported in 3–17% of angiosarcoma cases (Behjati et al., 2014; Je
et al., 2012; Italiano et al., 2012b). Of note, the PIK3CA mutational
status did not show correlation with the expression of downstream
protein kinases pS6K and/or p-4eBP1 (Italiano et al., 2012b). Over-
expression of pS6K and/or p-4eBP1 was observed in 42% of angio-
sarcoma cases. Two other downstream components, p-Akt and elF41,
were present in 85% and 87% of cases respectively.
Several drugs targeting downstream molecules in the PI3K/AKT/
mTOR pathway have been investigated (Wada et al., 2015). Treatment
of angiosarcoma cell lines with a PI3K inhibitor (LY294002) and PI3K/
mTOR inhibitor (NVP-BEZ235) yielded 80% growth reduction (Wada
et al., 2015). Treatment with mTOR inhibitor rapamycin resulted in
significant reduction of cell proliferation in vitro (Du et al., 2013),
whereas a 50–60% growth reduction was seen upon treatment with
mTOR inhibitor everolimus (Wada et al., 2015). Combination of ever-
olimus with doxorubicin did not yield a synergistic effect (Young et al.,
2014). The Akt kinase inhibitor MK2206 failed to suppress cell growth
(Wada et al., 2015). However, targeting PDK1 (Pyruvate Dehy-
drogenase Kinase 1, a downstream signal of PI3K which activates 20
substrates) showed more promising results. PDK1 inhibitor OSU-03012
inhibited growth of both ISOS-1 and ISO-HAS cell lines in a dose-de-
pendent manner (Wada et al., 2015). Also, silencing of PDK1 with
siRNA reduced pS6 and p4E-BP1 protein expression.
mTOR Inhibition has not yet been tested in a specific angiosarcoma
population. However, two out of three angiosarcoma patients included
in a phase II trial of everolimus reached the primary endpoint of
Progression Free Rate at 16 weeks (Yoo et al., 2013), compared to 27%
in the overall group of bone and soft tissue sarcoma patients. In addi-
tion, partial response to everolimus 10mg/day was reported in two
other angiosarcoma patients, with PFS of 6 and 12 months, respectively
(Zhang et al., 2017). Overall survival was 10 and 18 months and
treatment was well tolerated.
2.2.3. p16(INK4A) pathway
Genetic alterations in the tumor suppressor gene CDKN2A (Cyclin
Dependent Kinase Inhibitor 2A, also known as Ink4a/Arf) in angio-
sarcoma were first described in primary angiosarcoma of the liver
(Tannapfel et al., 2001). The Ink4a/Arf locus encodes the cycle-reg-
ulatory proteins p14(ARF) and p16(INK4a). Loss of p16(INK4A) results
in immortalization of cells and is often caused by hypermethylation of
CDKN2A p16(INK4A) promoter, as was the case in 12/17 (71%) of liver
angiosarcomas (Tannapfel et al., 2001). Inactivation of p16(INK4a) in
endothelial cells specifically resulted in defects in motility, morpho-
genesis and cytoskeletal organization (Kan et al., 2012). Furthermore, a
higher proliferation rate was seen. In 40% (9/23) of angiosarcoma cases
of unknown origin, immunohistochemical p16 expression was absent,
indicating that loss of expression had occurred (Knosel et al., 2014).
Whereas in other types of STS loss of p16 was associated with poor
overall survival, no significant difference in survival was noted for
angiosarcoma patients. This might be explained by the relatively small
numbers.
More recent genomic studies revealed loss of CDKN2A in 26% (9/
34) of angiosarcoma cases of different origins (Murali et al., 2015). In
addition, homozygous deletion of CDKN2A was found in 3 out of 10
cases of cardiac angiosarcoma which were analyzed by whole genome
analysis (Leduc et al., 2017). In theory, as CDKN2A negatively regulates
CDK4 and -6, angiosarcomas with CDKN2A loss might benefit from
treatment with CDK4/6 inhibitors such as palbociclib.
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2.3. Other genetic alterations
2.3.1. MYC
One of the most well-known genetic alterations in angiosarcoma is
high level amplification of MYC, a proto-oncogene involved in regula-
tion of cellular proliferation, differentiation and apoptosis.
Amplification is predominantly seen in secondary angiosarcoma related
to radiation therapy or chronic lymphedema, with reported prevalence
of 54–100%, compared to 0–7% in primary angiosarcoma (Huang et al.,
2016; Guo et al., 2011; Fraga-Guedes et al., 2015; Shon et al., 2014;
Mentzel et al., 2012). Most studies report a much higher prevalence in
radiotherapy-associated angiosarcoma of the breast compared to other
localizations (90–100% vs 25% respectively), although only a very
limited number of non-breast secondary angiosarcoma cases has been
analyzed. Analysis of 23 cases of cutaneous angiosarcoma of UV-ex-
posed skin showed amplification in 17% of cases by FISH (Shon et al.,
2014). The prognostic value of MYC amplification is yet to be de-
termined, though there is some evidence of a negative correlation with
survival (Huang et al., 2016; Fraga-Guedes et al., 2015). However, in
UV-related cutaneous angiosarcoma, presence of MYC amplification
was not correlated with clinical outcome (Shon et al., 2014).
As yet, the exact role of MYC in pathogenesis of (secondary) an-
giosarcoma remains unclear. Its subsequent potential as a target for
treatment is still under investigation but bromodomain (BET) inhibitors
might be effective inhibitors of the c-MYC protein.
2.3.2. Fusion genes
Other genetic alterations found in angiosarcoma include two dif-
ferent fusion genes, CEP85L-ROS1 (Giacomini et al., 2013) and CIC-
LEUTX (Huang et al., 2016). ROS1 kinase can be targeted with ROS1
kinase inhibitors, however this fusion was only detected in 1/34 (2.9%)
of angiosarcoma cases and further experiments were not reported. CIC
fusions are not yet targetable.
2.4. Other targets
In addition to the abovementioned pathways and genetic alterations
studied in angiosarcoma, several other potential targets have been de-
scribed.
2.4.1. HSP90
Heat shock protein 90 (HSP90) regulates various cancer-related
proteins by stabilizing and activating proteins required for survival of
malignant cells. In angiosarcoma cell lines and patient samples (n=4),
levels of HSP90 protein expression were increased compared to controls
(Yamada-Kanazawa et al., 2017). The HSP90 inhibitor ganetespib in-
duced apoptosis as monotherapy, and an additive to synergistic effect
was seen upon combination with docetaxel and paclitaxel. Knockdown
of HSP90 selectively suppressed several downstream targets of VEGF
signaling in angiosarcoma cells, but did not exert a direct effect on
VEGFR2.
2.4.2. CD30
Expression of CD30, a member of the TNF receptor superfamily, was
present in 34% (31/91) of angiosarcoma cases (Alimchandani et al.,
2014). CD30 antibody drug conjugates may therefore present a po-
tential therapy for patients with strongly positive CD30 angiosarcoma.
Brentuximab is a CD30 antibody drug conjugate, delivering the highly
toxic anti-microtubule agent momomethyl auristatin E to CD30-positive
cells. Only one case of brentuximab treatment of angiosarcoma has
been described so far in a patient with CD30-positive secondary an-
giosarcoma of the breast, after failure of first line paclitaxel, showing a
response after 2 cycles but progression after 4 cycles (Holm et al.,
2016).
2.4.3. YAP
Yes-associated protein (YAP) is a downstream protein in the Hippo-
pathway, which is involved in regeneration and cell proliferation. Upon
inactivation of the Hippo-pathway, YAP moves to the nucleus and ac-
tivates genes involved in cell proliferation and the suppression of
apoptosis. It has been suggested that YAP-activation leads to increased
expression of survivin in endothelial cells (Tsuneki and Madri, 2014). In
angiosarcoma, survivin expression was found in 86% (73/85) of cases
(Tsuneki et al., 2017). Expression of YAP was present in 85% (72/85),
of which 90% showed nuclear staining, thus indicating the Hippo-
pathway to be switched off. Presence of survivin or nuclear YAP ex-
pression did not significantly correlate with patient survival. The ISO-
HAS angiosarcoma cell line showed survivin expression, and suppres-
sion of cell growth occurred after treatment with survivin inhibitor
YM155. These findings suggest that activated YAP and/or survivin
could be a target for therapy.
A proposed underlying mechanism of the abovementioned changes
in survivin and nuclear YAP expression is found in genetic depletion of
CD31 (Tsuneki and Madri, 2014). Further analysis indicated a small
population of CD31low cells was present in the majority of angio-
sarcoma tumor samples (11/17; 65%) (Venkataramani et al., 2018). In
addition, a population of CD31low cells of up to 60% was found in the
AS-M5 cell line. These CD31low cells were highly proliferative, resistant
to stress and more tumorigenic compared to CD31high cells. Interest-
ingly, CD31low cells were also more resistant to doxorubicin. Upon
treatment with pazopanib, which is known to also inhibit YAP, CD31low
cells were resensitized to doxorubicin treatment.
2.4.4. ALT/DAXX
Alternative lengthening of telomeres (ALT) is a mechanism involved
in a subset of cancers which maintain telomere lengths without de-
tectable telomerase activity. The ALT phenotype has been frequently
associated with loss of expression of ATRX (α-thalassemia/mental re-
tardations syndrome X-linked) and DAXX (death domain-associated 6).
Receptor expression of ATRX was absent in 6% (7/118) of angio-
sarcoma cases (Panse et al., 2019). Absence of ATRX in angiosarcomas
was significantly associated with inferior Event Free Survival and lo-
calization of the primary tumor in the deep soft tissue. DAXX expression
was retained in all cases examined. Of note, absence of ATRX was re-
ported in 21% (16/77) of primary angiosarcomas in another study (Liau
et al., 2015). A tumor with ALT-phenotype may be sensitive to ATR
inhibitors, although conflicting results have been reported and the
strategy of targeting ALT phenotype should be further investigated
(Flynn et al., 2015; Deeg et al., 2016).
2.4.5. Notch
Notch signaling is involved in regulation of stem cells and pro-
genitor cells, through control of gene transcription. Mutations in
Notch1 have been found in angiosarcoma (Murali et al., 2015), and
inhibition of Notch signaling has led to development of malignant
vascular tumors in mice (Dill et al., 2012). Decreased Notch1 expression
was found in 24% (29/123) of angiosarcoma cases and was associated
with advanced disease and cutaneous site of origin (Panse et al., 2019).
Notch2 expression was lost in 16% (16/103) of cases and was asso-
ciated with worse disease specific survival and visceral site of origin. It
is known that Notch can act both oncogenic as well as tumor sup-
pressive depending on the cellular context (Nowell and Radtke, 2017).
Based on the before mentioned results, Notch appears to have a tumor
suppressive role in angiosarcoma. However, 1 out of 8 angiosarcoma
patients included in a recent phase 1 trial with Notch-inhibitor
LY3039478 had unconfirmed partial response (Mir et al., 2018). These
conflicting data emphasize the need for further research into the exact
role and targetability of Notch signaling in angiosarcoma subtypes.
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2.5. Epigenetics
Besides attempts to target specific mutations and their downstream
pathways, another emerging field in cancer treatment lies in epige-
netics. This involves changes in gene activity without altering the DNA
sequence, thus leading to modifications in transcription. Epigenetic
mechanisms can be divided into four categories: DNA methylation,
histone modification, ATP‐dependent nucleosome remodeling, and
microRNAs or other noncoding RNAs. So far, in angiosarcoma only
microRNAs (miRNAs) have been described. MiRNAs are capable of
inflicting post-transcriptional changes, thus controlling target gene ex-
pression by interfering in the RNA pathway. In angiosarcoma, down-
regulation of miR-497-5p was found (Chen et al., 2016). Further ana-
lysis showed reduced growth both in vitro and in vivo growth upon
inhibition of miR-497-5p or its target gene KCa3.1. In addition, ex-
pression of miR-210 was markedly decreased in angiosarcoma cells,
both in vitro and in vivo (Nakashima et al., 2017). Further analysis of
two putative targets of miR-210, E2F3 and Ephrin A3, revealed upre-
gulation of protein expression in angiosarcoma tumor cells. E2F3 is a
transcription factor and involved in regulation of apoptotic response,
cell proliferation and differentiation. Ephrin A3 is a member of the
ephrin family, regulating vascular development. A significant reduction
of angiosarcoma cells was seen upon E2F3 or Ephrin A3 knockdown,
thus indicating a potential target for growth inhibition (Nakashima
et al., 2017).
2.6. Immunotherapy
Immunotherapy has been a major breakthrough in the treatment of
several types of cancer, such as melanoma and lung cancer.
Immunotherapy can be divided into different main strategies, including
cytokines (e.g. IL-2, IFN-α), cell-based therapies (vaccines, adoptive cell
therapy) and immune checkpoint blockade (anti-CTLA-4, anti-PD-1,
anti-PD-L1).
In the field of sarcoma, to date immunotherapy has not given major
clinical breakthroughs, but interesting signals have been observed. In
angiosarcoma specifically, only limited research has been published
yet. One of the targets of immunotherapy is the tumor-infiltrating
lymphocyte (TIL). A higher number of CD8(+) TILs was found to be
associated with higher survival by immunohistochemical evaluation of
55 cutaneous angiosarcoma samples (Fujii et al., 2014). Moreover,
presence of interferon-γ producing CD4(+) and CD8(+) peripheral
blood mononuclear cells was significantly higher compared to healthy
controls and melanoma patients. Further stimulation of already present
CD8(+) cells might provide a new strategy for angiosarcoma treat-
ment.
Based on the presence of CD8(+) TILs in cutaneous angiosarcomas,
Programmed Death Ligand 1 (PD-L1) expression was examined in this
subgroup and found present in 30–40% of cutaneous angiosarcoma
cases (Honda et al., 2017; Shimizu et al., 2017). In one study, PD-L1
expression was found to be an independent prognostic marker for worse
survival in stage 1 patients (Shimizu et al., 2017). In contrast, in an-
other study a high infiltration of PD-1 positive lymphocytes into the
tumor was significantly related to favorable survival in stage 1 cuta-
neous angiosarcoma patients by univariate and multivariate analysis
(hazard ratio 0.38, p= 0.021, CI 0.16−0.86) (Honda et al., 2017). In
an additional study with 24 primary angiosarcomas, 66% of cases
showed PD-L1 expression (Botti et al., 2017). Of interest, PD-L1 posi-
tivity was not only found in cases of cutaneous origin but also in soft
tissue and breast angiosarcomas.
Hence, PD-L1 expression appears to be present in a subset of an-
giosarcomas, but the relationship between PD-1 and PD-L1-expression
and susceptibility to anti-PD-1 treatment has yet to be established in
general. So far, clinical data of immune checkpoint inhibitors in an-
giosarcoma are scarce. Combination of nivolumab (anti-PD-1 antibody)
and ipilimumab (anti-CTLA4 antibody) in patients with advanced
sarcoma yielded an objective response in one out of 3 angiosarcoma
patients participating (D’Angelo et al., 2018). Details with regard to the
tumor characteristics of this responsive patient have not yet been
published. Pembrolizumab was investigated in combination with cy-
clophosphamide in a phase II trial for advanced sarcoma and GIST
patients (Toulmonde et al., 2017). No specific results regarding an-
giosarcoma patients have been reported yet. Two cases of checkpoint
inhibitors in angiosarcoma have been published, reporting angio-
sarcoma of the nose yielding a PR on pembrolizumab (Sindhu et al.,
2017), and nivolumab treatment of a PD-L1 negative angiosarcoma of
the scalp remarkably resulting in durable complete response (Hofer
et al., 2018). Of note, all published responses to checkpoint inhibitors
have been in cutaneous angiosarcoma. The combination of PD-L1 in-
hibitor avelumab and paclitaxel is currently under investigation in a
phase 2 trial (NCT03512834). This study includes all clinical subtypes
of locally advanced and metastatic angiosarcoma, independent of PD-
L1 expression.
Based on promising results in synovial sarcoma patients with T-cell
based immunotherapy directed against cancer testis antigen NY-ESO-1,
expression was also investigated in angiosarcoma samples. NY-ESO-1
expression was demonstrated in 7/54 (13%) angiosarcoma samples (Lai
et al., 2012; Iura et al., 2017). MAGEA4 is another cancer testis antigen
and is known to be recognized by specific cytotoxic T lymphocytes as
well. MAGEA4 expression was present in 41% (12/29) of angio-
sarcomas, with strong MAGEA4 expression in about 20% of cases (Iura
et al., 2017). Application of NY-ESO-1 or MAGEA4 directed therapy has
not yet been reported in angiosarcoma.
3. Future perspectives
The prognosis of angiosarcoma patients remains poor and im-
proving their treatment opportunities is necessary. Due to the rarity and
heterogeneity of angiosarcomas, attempts to improve its treatment have
been limited. Although a bench to bedside approach is advocated as the
ideal sequence of medical science, there are only a few clear examples
of this sequence. Therefore, we suggest that future research should
focus on both further understanding of known promising preclinical
targets, as well as on acquiring knowledge based on clinical, genetic
and immunological large datasets of angiosarcomas.
As for known promising targets, we here described the PI3K/AKT/
mTOR pathway, SFRP2 and YAP/survivin as potentially interesting
targets for further research. Furthermore, extended investigation of
combination therapies such as Tie2 kinase and VEGF inhibition, or
combined mTOR and MEK inhibition, could help to improve efficacy
and overcome treatment resistance. The first promising signs with
checkpoint inhibitors in cutaneous angiosarcomas also deserve further
study. Next Generation Sequencing panel screening might help speed
up our knowledge of drivers and could also help to identify targets for
individualized treatment. Genetic aberrations should be validated by
investigating their downstream functional components and new treat-
ments should be tested pre-clinically. Furthermore, genomic and phe-
notypic data should be merged to understand the differences in biology
and response to treatments in the different clinical angiosarcoma sub-
types. This would improve and fasten the selection of the right patients
for the right treatments.
Several promising initiatives have been set up to enable the col-
lection of data of larger numbers of patients, such as the AACR GENIE
project in which cancer genomic data of cancer patients are integrated
with clinical outcome data (AACR Project GENIE, 2017). This database
is freely accessible and contains about 1400 STS samples, including
almost 100 angiosarcoma patients. Another revolutionary project is the
Angiosarcoma Project (Dunphy et al., 2018), which also provides
publicly available data. They involve angiosarcoma patients themselves
to provide saliva, blood and tumor samples to perform whole exome
sequencing. In addition, their clinical data are collected. By setting up
international networks and freely accessible data collections, these
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projects are extremely valuable and provide the opportunity to achieve
the progress we desperately need in angiosarcoma.
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